Neuroscience 2005 Abstract
| Presentation Number: | 227.8 |
|---|---|
| Abstract Title: | The CB1 receptor antagonist AM 251 inhibits cocaine-enhanced brain stimulation reward and the progressive-ratio break-point for cocaine self-administration in rats. |
| Authors: |
Pak, A. C.*1
; Xi, Z. X.1
; Gilbert, J.1
; Peng, X. Q.1
; Gardner, E.1
1Intramural Research Program, National Inst. on Drug Abuse, Baltimore, MD |
| Primary Theme and Topics |
Disorders of the Nervous System - Addiction and Drugs of Abuse -- Addiction: Treatment |
| Secondary Theme and Topics | Disorders of the Nervous System<br />- Addiction and Drugs of Abuse<br />-- Addiction: Behavioral pharmacology |
| Session: |
227. Addiction Treatment: Novel Mechanisms Poster |
| Presentation Time: | Sunday, November 13, 2005 11:00 AM-12:00 PM |
| Location: | Washington Convention Center - Hall A-C, Board # VV70 |
| Keywords: | endocannabinoid, intracranial self-stimulation, addiction, SR141716A |
Deletion of cannabinoid CB1 receptors or SR141716A-induced blockade of CB1 receptors abolishes or significantly attenuates THC, heroin, ethanol, nicotine, but not cocaine self-administration or conditioned place preference, suggesting that CB1 receptor antagonists could be promising in treatment of drug addiction (Le Foll and Goldberg, 2005). It was also reported that SR141716A dose-dependently inhibits cocaine- or cocaine-associated cue-triggered reinstatement of drug-seeking behavior (De Vries et al., 2001). In the present study, we examined whether the novel CB1 receptor antagonist AM 251, which is more potent and selective than SR141716A for CB1 receptors, attenuates cocaine-induced enhancement of brain stimulation reward and cocaine self-administration under a progressive-ratio reinforcement schedule. We found that pretreatment with AM 251 (0.3, 1, 3 mg/kg, i.p., 30 min prior to cocaine) dose-dependently attenuates (74, 65, 96%, respectively) 2 mg/kg cocaine-induced enhancement of brain stimulation reward in male Long-Evans rats. Systemic administration of AM 251 (1, 3, 10 mg/kg) also dose-dependently lowers the break-point for cocaine (0.5 mg/kg/infusion) self-administration by 37, 43, 60%, respectively. Taken together, these data suggest that blockade of CB1 receptors significantly attenuates cocaine’s rewarding effects in rats. This finding supports the potential use of AM 251 or other CB1-selective antagonists in treatment of cocaine addiction.
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2005 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2005. Online.
Copyright © 2005-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
